Hero BG

An Over 40 Year Tradition of Winning
Pittsburgh Personal Injury Cases

TELL US WHAT HAPPENED Click to Call
CONTACT THE ATTORNEYS
Berger & Lagnese, LLC

New Study Finds Valsartan May Not Reduce Occurence of Atrial Fibrillation

Valsartan (Diovan), a blood pressure drug, may not reduce the occurrence of artrial fibrillation as suggested in earlier research.  Atrial fibrillation is a common cardiac arrhythmia or abnormal heart rhythm that can sometimes cause a heart attack or stroke.

The new study, which was published in the New England Journal of Medicine, involved 1,442 people who had two or more recent episodes of atrial fibrillation. Half of the participants were given valsartan, while the other half received a placebo.

Over the course of a year, atrial fibrillation reoccurred about equal in both groups, 51.4% of those taking valsartan and 52.1% of those taking the placebo. 

The study therefore concluded that treatment with valsartan could not be linked to a reduction in the reoccurrence of atrial fibrillation.


Get free information about atrial fibrillation from the medical malpractice attorneys at Berger & Lagnese.